filmov
tv
Expert report on immune checkpoint inhibitors for dMMR Colorectal Cancer
Показать описание
Julien Taieb discusses abstracts presented at ESMO Congress 2022:
- LBA23: Avelumab versus standard second-line treatment chemotherapy in metastatic colorectal cancer (mCRC) patients with microsatellite instability (MSI): the SAMCO-PRODIGE 54 randomised phase II trial
- LBA7: Neoadjuvant immune checkpoint inhibition in locally advanced MMR-deficient colon cancer: The NICHE-2 study
Produced by the European Society for Medical Oncology
This video was supported with an educational grant from Roche.
The study results covered, and the presenter of this expert video, have been selected exclusively by ESMO.
- LBA23: Avelumab versus standard second-line treatment chemotherapy in metastatic colorectal cancer (mCRC) patients with microsatellite instability (MSI): the SAMCO-PRODIGE 54 randomised phase II trial
- LBA7: Neoadjuvant immune checkpoint inhibition in locally advanced MMR-deficient colon cancer: The NICHE-2 study
Produced by the European Society for Medical Oncology
This video was supported with an educational grant from Roche.
The study results covered, and the presenter of this expert video, have been selected exclusively by ESMO.
0:05:30
0:04:58
0:07:00
0:03:41
0:00:58
0:05:33
0:29:57
0:04:31
0:14:42
0:29:56
0:01:05
0:07:25
0:40:21
0:01:07
0:00:42
1:02:47
0:01:20
0:05:34
0:13:29
0:13:01
1:01:45
0:02:53
0:01:40
0:05:24